Bio-Rad Laboratories (BIO) Payables (2009 - 2026)

Bio-Rad Laboratories (BIO) has reported Payables for 18 consecutive years, with $143.5 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Payables rose 3.02% year-over-year to $143.5 million in Q2 2026; TTM through Jun 2026 was $143.5 million, a 3.02% increase from a year earlier, with the FY2025 full-year figure at $129.0 million, up 5.48% from the prior year.
• Payables was $143.5 million for Q2 2026 at Bio-Rad Laboratories, up from $133.1 million in the prior quarter.
• Over five years, Payables peaked at $161.0 million in Q1 2023 and troughed at $102.8 million in Q1 2024.
• A 5-year average of $136.1 million and a median of $136.5 million in 2022 frame the typical range for Payables.
• Across the five-year window, Payables sank 36.17% in 2024 and soared 34.21% in 2025, its largest moves.
• Over 5 years, Payables stood at $135.0 million in 2022, then rose by 7.08% to $144.6 million in 2023, then retreated by 15.42% to $122.3 million in 2024, then grew by 5.48% to $129.0 million in 2025, then gained by 11.24% to $143.5 million in 2026.
• The last three Payables figures came in at $143.5 million (Q2 2026), $133.1 million (Q1 2026), and $129.0 million (Q4 2025), per Business Quant data.